Travere Therapeutics (TVTX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Travere Therapeutics (TVTX) over the last 13 years, with Q2 2025 value amounting to $2.1.
- Travere Therapeutics' Debt to Equity changed N/A to $2.1 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1, marking a year-over-year change of. This contributed to the annual value of $1.16 for FY2024, which is N/A changed from last year.
- According to the latest figures from Q2 2025, Travere Therapeutics' Debt to Equity is $2.1.
- Travere Therapeutics' 5-year Debt to Equity high stood at $2.1 for Q2 2025, and its period low was -$2.25 during Q3 2024.
- For the 5-year period, Travere Therapeutics' Debt to Equity averaged around $0.32, with its median value being $0.06 (2023).
- In the last 5 years, Travere Therapeutics' Debt to Equity crashed by 7026.72% in 2021 and then surged by 56691.94% in 2022.
- Travere Therapeutics' Debt to Equity (Quarter) stood at $0.02 in 2021, then soared by 566.92% to $0.16 in 2022, then tumbled by 63.74% to $0.06 in 2023, then skyrocketed by 1862.55% to $1.16 in 2024, then surged by 80.82% to $2.1 in 2025.
- Its Debt to Equity stands at $2.1 for Q2 2025, versus $2.09 for Q1 2025 and $1.16 for Q4 2024.